Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant radiotherapy plus trifluridine/tipiracil for locally advanced rectal cancer
ChiCTR2200063142Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in rectal cancer, sponsored by Shandong Cancer Hospital. Primary endpoints: Pathological complete response rate and Safety. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2200063142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063142.